BioInvent and Attana has signed a three-month evaluation agreement. BioInvent is a clinical-stage company that discovers and develops antibodies for cancer therapy. Based on extensive knowledge in immunology, cancer biology and antibody biology, BioInvent generates innovative immuno-oncology drug candidates.

Attana will in May install Attana Cell? 250 instrument and train users at BioInvents labs in Lund. During the evaluation period cell- and sera-based assays will be performed to study interactions between antibodies and target cells.